Back

Effector T cells in poorly perfused tumor regions exhibit a distinct signature of augmented IFN response and reduced PD-1 expression

Riera-Borrull, M.; Tejedor Vaquero, S.; Cerdan Porqueras, V.; Aramburu, J.; Lopez-Rodriguez, C.

2024-07-08 immunology
10.1101/2024.07.05.601540 bioRxiv
Show abstract

Effector T lymphocytes are avid glucose consumers, but can function in the nutrient-poor environments of tumors. However, availability of blood-delivered nutrients throughout the tumor is not homogeneous, and how this affects effector T cells is not well known. Here we have isolated tumor-infiltrating T lymphocytes (TILs) from mouse solid tumors by their capacity to capture blood-transported probes, and compared them with glucose-restricted T cells. Glucose restriction in vitro arrested cell proliferation but reduced only moderately the induction of hallmark glucose-dependent cytokines interferon gamma (IFN{gamma}) and IL-17. In vivo, effector TILs with reduced access to blood had characteristics of glucose-restricted cells, such as reduced expression of IFN{gamma} and genes associated with cell proliferation. However, they expressed more CXCR3, which identifies effective antitumor T lymphocytes, showed an enhanced IFN response signature, and had reduced expression of surface PD-1. We also identified genes regulated by the enzyme ACSS2, which allows TILs to sustain gene expression in glucose-poor environments. Thus, effector T lymphocytes infiltrating tumors express different gene signatures in regions with different accessibility to blood, and can maintain specific glucose-dependent responses even in poorly perfused tumor regions. Our results can help better understand nutrient-dependent TIL heterogeneity in changing tumor microenvironments. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=102 SRC="FIGDIR/small/601540v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@115d6beorg.highwire.dtl.DTLVardef@c56904org.highwire.dtl.DTLVardef@71b324org.highwire.dtl.DTLVardef@a804d0_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cancer Immunology Research
34 papers in training set
Top 0.1%
18.6%
2
Cell Reports
1338 papers in training set
Top 1%
12.3%
3
eLife
5422 papers in training set
Top 13%
6.4%
4
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.2%
6.3%
5
iScience
1063 papers in training set
Top 2%
4.8%
6
Cell
370 papers in training set
Top 4%
4.8%
50% of probability mass above
7
Journal of Experimental Medicine
106 papers in training set
Top 1%
3.1%
8
Frontiers in Immunology
586 papers in training set
Top 3%
2.7%
9
OncoImmunology
22 papers in training set
Top 0.1%
2.7%
10
Cell Reports Medicine
140 papers in training set
Top 2%
2.4%
11
The Journal of Immunology
146 papers in training set
Top 0.7%
2.1%
12
Science Immunology
81 papers in training set
Top 1.0%
1.9%
13
Scientific Reports
3102 papers in training set
Top 56%
1.8%
14
Theranostics
33 papers in training set
Top 0.7%
1.5%
15
Cell Metabolism
49 papers in training set
Top 1%
1.5%
16
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.2%
1.3%
17
Cell Systems
167 papers in training set
Top 9%
1.2%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 38%
1.2%
19
Nature Communications
4913 papers in training set
Top 56%
1.2%
20
Immunity
58 papers in training set
Top 4%
0.7%
21
Cancer Cell
38 papers in training set
Top 2%
0.7%
22
EMBO reports
136 papers in training set
Top 6%
0.7%
23
PLOS ONE
4510 papers in training set
Top 70%
0.7%
24
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%
25
Cells
232 papers in training set
Top 7%
0.7%
26
Cancer Research Communications
46 papers in training set
Top 2%
0.6%
27
Nature Immunology
71 papers in training set
Top 2%
0.6%
28
Blood Advances
54 papers in training set
Top 1%
0.6%
29
Cellular & Molecular Immunology
14 papers in training set
Top 2%
0.6%
30
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.6%